INmune Bio, Inc. (INMB)
2.36
+0.12
(+5.36%)
USD |
NASDAQ |
Sep 02, 16:00
2.36
0.00 (0.00%)
After-Hours: 20:00
INmune Bio Enterprise Value : 44.94M for Sept. 1, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 01, 2026 | 44.94M |
| August 31, 2026 | 46.60M |
| August 28, 2026 | 47.43M |
| August 27, 2026 | 49.36M |
| August 26, 2026 | 50.61M |
| August 25, 2026 | 50.19M |
| August 24, 2026 | 48.26M |
| August 21, 2026 | 47.15M |
| August 20, 2026 | 42.73M |
| August 19, 2026 | 44.66M |
| August 18, 2026 | 41.34M |
| August 17, 2026 | 41.90M |
| August 14, 2026 | 43.00M |
| August 13, 2026 | 40.51M |
| August 12, 2026 | 39.41M |
| August 11, 2026 | 40.51M |
| August 10, 2026 | 41.62M |
| August 07, 2026 | 40.65M |
| August 06, 2026 | 35.81M |
| August 05, 2026 | 35.54M |
| August 04, 2026 | 35.81M |
| August 03, 2026 | 34.15M |
| July 31, 2026 | 31.39M |
| July 30, 2026 | 31.94M |
| July 29, 2026 | 29.73M |
| Date | Value |
|---|---|
| July 28, 2026 | 30.28M |
| July 27, 2026 | 30.84M |
| July 24, 2026 | 27.79M |
| July 23, 2026 | 30.56M |
| July 22, 2026 | 33.88M |
| July 21, 2026 | 37.47M |
| July 20, 2026 | 38.03M |
| July 17, 2026 | 35.54M |
| July 16, 2026 | 40.24M |
| July 15, 2026 | 40.24M |
| July 14, 2026 | 38.85M |
| July 13, 2026 | 34.43M |
| July 10, 2026 | 36.64M |
| July 09, 2026 | 32.49M |
| July 08, 2026 | 30.56M |
| July 07, 2026 | 31.11M |
| July 06, 2026 | 29.04M |
| July 02, 2026 | 30.01M |
| July 01, 2026 | 29.45M |
| June 30, 2026 | 28.07M |
| June 29, 2026 | 23.22M |
| June 26, 2026 | 17.90M |
| June 25, 2026 | 19.76M |
| June 24, 2026 | 16.04M |
| June 23, 2026 | 17.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.45B |
| Oncolytics Biotech, Inc. | 101.03M |
| Sangamo Therapeutics, Inc. | 59.69M |
| Sarepta Therapeutics, Inc. | 2.510B |
| Anixa Biosciences, Inc. | 96.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.273M |
| Total Expenses (Quarterly) | 1.273M |
| EPS Diluted (Quarterly) | -0.0476 |
| Earnings Yield | -29.34% |
| Normalized Earnings Yield | -30.01 |